Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | STS | P08842 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.41 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.41 |
| ▸ | GLS | O94925 | 2/20 | 0.40 |
| ▸ | TACR1 | P25103 | 4/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | CETP | P11597 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | RHOC | P08134 | 1/20 | 0.36 |
| ▸ | RHOA | P61586 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4276575 | 1.00 | CYP1A2 (0.43) | CYP1A2POLBCYP3A4CYP2C19STS | |
| SCHEMBL8374022 | 0.94 | CYP1A2 (0.40) | CYP1A2POLBCYP3A4CYP2C19STS | |
| SCHEMBL4272965 | 0.86 | HSD17B10 (0.52) | STSEPHX2CXCR3GLSALDH1A1 | |
| SCHEMBL4272968 | 0.86 | HSD17B10 (0.52) | STSEPHX2CXCR3GLSALDH1A1 | |
| SCHEMBL4276665 | 0.86 | HSD17B10 (0.52) | STSEPHX2CXCR3GLSALDH1A1 | |
| SCHEMBL4274713 | 0.86 | HSD17B10 (0.48) | STSEPHX2CXCR3GLSRHOC | |
| SCHEMBL6863335 | 0.84 | STS (0.56) | STSEPHX2CXCR3GLSTACR1 | |
| SCHEMBL19112893 | 0.83 | EPHX2 (0.40) | STSEPHX2CXCR3TACR1ALDH1A1 | |
| SCHEMBL1444654 | 0.82 | STS (0.52) | STSEPHX2CXCR3GLSTACR1 | |
| SCHEMBL17860940 | 0.80 | HSD17B10 (0.47) | STSEPHX2GLSTACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3189839-B1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | PRAXIS PREC MEDICINES INC (US) | 2020-05-20 | — | — | EP | disclosed |
| EP-2300007-B1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | TARO PHARMACEUTICALS INC (CA) | 2018-04-18 | — | — | EP | disclosed |
| EP-3189839-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | Taro Pharmaceuticals Inc. (CA) | 2017-07-12 | — | — | EP | disclosed |
| US-20160175315-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS, LTD. (CA) | 2016-06-23 | — | — | US | disclosed |
| US-9096522-B2 | N-piperidinyl acetamide derivatives as calcium channel blockers | Zalicus Pharmaceuticals, Ltd. (CA) | 2015-08-04 | — | — | US | disclosed |
| US-20140011996-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2014-01-09 | — | — | US | disclosed |
| US-8569344-B2 | N-piperidinyl acetamide derivatives as calcium channel blockers | ZALICUS PHARMACEUTICALS LTD. (CA) | 2013-10-29 | — | — | US | disclosed |
| US-20130065926-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MARK G. DEGIACOMO, CHAPTER 7 TRUSTEE OF EPIRUS BIOPHARMACEUTICALS, INC. | 2013-03-14 | — | — | US | disclosed |
| US-8377968-B2 | N-piperidinyl acetamide derivatives as calcium channel blockers | Zalicus Pharmaceuticals, Ltd. (CA) | 2013-02-19 | — | — | US | disclosed |
| US-20090298883-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MARK G. DEGIACOMO, CHAPTER 7 TRUSTEE OF EPIRUS BIOPHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065926-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1H, CACNA1B | CYP1A2 1964/4885POLB 3061/4885CYP3A4 2701/4885 |
| US-20140011996-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1H, CACNA1B | CYP1A2 1964/4885POLB 3061/4885CYP3A4 2701/4885 |
| US-20090298883-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1H, CACNA1B | CYP1A2 1964/4885POLB 3061/4885CYP3A4 2701/4885 |
| US-20160175315-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1H, CACNA1B | CYP1A2 1964/4885POLB 3061/4885CYP3A4 2701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.